642 related articles for article (PubMed ID: 8905207)
21. Hemorheological mechanisms in Alzheimer's disease.
Chang CY; Liang HJ; Chow SY; Chen SM; Liu DZ
Microcirculation; 2007 Aug; 14(6):627-34. PubMed ID: 17710633
[TBL] [Abstract][Full Text] [Related]
22. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.
Targher G; Bertolini L; Zoppini G; Zenari L; Falezza G
Diabet Med; 2005 Aug; 22(8):999-1004. PubMed ID: 16026364
[TBL] [Abstract][Full Text] [Related]
23. Von Willebrand factor in diabetic angiopathy.
Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
[TBL] [Abstract][Full Text] [Related]
24. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
[TBL] [Abstract][Full Text] [Related]
25. Do hemorheological alterations play any role in the development of thrombotic events in Behçet's disease?
Vayá A; Ricart J; Todolí J; Micó L; Contreras T; Aznar J
Clin Hemorheol Microcirc; 2004; 30(3-4):411-4. PubMed ID: 15258375
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy].
Fang YH; Zhang JP; Zhou SX; Zheng JF; Yu YW; Yan SG; Fan WK; Cheng YS
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):729-31. PubMed ID: 15958323
[TBL] [Abstract][Full Text] [Related]
27. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia.
Aso Y; Yoshida N; Okumura K; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Clin Chim Acta; 2004 Oct; 348(1-2):139-45. PubMed ID: 15369747
[TBL] [Abstract][Full Text] [Related]
28. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
Zareba W; Pancio G; Moss AJ; Kalaria VG; Marder VJ; Weiss HJ; Watelet LF; Sparks CE
Thromb Haemost; 2001 Sep; 86(3):791-9. PubMed ID: 11583309
[TBL] [Abstract][Full Text] [Related]
29. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
[TBL] [Abstract][Full Text] [Related]
30. Plasma homocysteine and microvascular complications in type 1 diabetes.
Vaccaro O; Perna AF; Mancini FP; Iovine C; Cuomo V; Sacco M; Tufano A; Rivellese AA; Ingrosso D; Riccardi G
Nutr Metab Cardiovasc Dis; 2000 Dec; 10(6):297-304. PubMed ID: 11302003
[TBL] [Abstract][Full Text] [Related]
31. [Factor VIII/Ag (von Willebrand) and protein C. Erythrocyte deformability and aggregability. The risk parameters of retinal vein occlusion].
Cortinovis A; Crippa A; Crippa M
Minerva Med; 1994 May; 85(5):211-9. PubMed ID: 8028749
[TBL] [Abstract][Full Text] [Related]
32. [Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis].
Smyr KV; Shcherbak AV; Kozlovskaia LV; Sokolova IA; Bobkova IN; Podorol'skaia LV
Ter Arkh; 2010; 82(1):47-51. PubMed ID: 20364701
[TBL] [Abstract][Full Text] [Related]
33. Hemorheological disturbances in patients with chronic cerebrovascular diseases.
Szapary L; Horvath B; Marton Z; Alexy T; Demeter N; Szots M; Klabuzai A; Kesmarky G; Juricskay I; Gaal V; Czopf J; Toth K
Clin Hemorheol Microcirc; 2004; 31(1):1-9. PubMed ID: 15272148
[TBL] [Abstract][Full Text] [Related]
34. Effect of Sclerovit on endothelial dysfunction, hemorheological parameters, platelet aggregation, plasma concentration of homocysteine and progression of atherosclerosis in patients with vascular diseases.
Horvath B; Szapary L; Debreceni L; Feher G; Kenyeres P; Fulop A; Battyani I; Toth K
Clin Hemorheol Microcirc; 2009; 42(1):19-28. PubMed ID: 19363237
[TBL] [Abstract][Full Text] [Related]
35. Nutritional antioxidants, red cell membrane fluidity and blood viscosity in type 1 (insulin dependent) diabetes mellitus.
Osterode W; Holler C; Ulberth F
Diabet Med; 1996 Dec; 13(12):1044-50. PubMed ID: 8973886
[TBL] [Abstract][Full Text] [Related]
36. Improvement of hemorheological abnormalities in alcoholics by an oral antioxidant.
Marotta F; Safran P; Tajiri H; Princess G; Anzulovic H; Idéo GM; Rouge A; Seal MG; Idéo G
Hepatogastroenterology; 2001; 48(38):511-7. PubMed ID: 11379344
[TBL] [Abstract][Full Text] [Related]
37. Impact of pancreas and kidney transplantation on determinants of blood and plasma viscosity.
Mellinghoff AC; Reininger AJ; Wurzinger LJ; Landgraf R; Hepp KD
Clin Hemorheol Microcirc; 1998 Jul; 18(2-3):175-84. PubMed ID: 9699039
[TBL] [Abstract][Full Text] [Related]
38. [Cardiovascular risk factors in diabetic nephropathy].
Zimmermann J; Schramm L; Mulzer E; Heidbreder E; Henrich HA; Wanner C
Med Klin (Munich); 1997 Feb; 92(2):74-8. PubMed ID: 9139214
[TBL] [Abstract][Full Text] [Related]
39. Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.
Triolo G; Giardina E; Casiglia D; Scarantino G; Bompiani GD
Clin Exp Immunol; 1991 Apr; 84(1):53-8. PubMed ID: 2015712
[TBL] [Abstract][Full Text] [Related]
40. Plasma fibronectin, von Willebrand factor antigen, and blood rheology. Association with diabetic microvascular disease.
Solerte SB; Piovella F; Viola C; Schianca GC; Gamba G; Fioravanti M; Ferrari E
Acta Diabetol Lat; 1985; 22(3):239-46. PubMed ID: 3878055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
